Understand the source comparison
Best Peptides to Lose Visceral Fat Ranked: Clinical vs Research Compounds
Semaglutide (Wegovy) GLP-1 receptor agonist. Appetite suppression + direct adipocyte lipolysis 8.7% reduction at 68 weeks (STEP 1 imaging substudy) 0.25mg → 2.4mg weekly over 16–20 weeks Gold standard for visceral fat loss. FDA-approved, strongest clinical evi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semaglutide (Wegovy)
- GLP-1 receptor agonist. Appetite suppression + direct adipocyte lipolysis
- 8.7% reduction at 68 weeks (STEP 1 imaging substudy)
- 0.25mg → 2.4mg weekly over 16–20 weeks
- Gold standard for visceral fat loss. FDA-approved, strongest clinical evidence
- Tirzepatide (Zepbound)
- Dual GIP/GLP-1 agonist. Enhanced insulin sensitivity in visceral adipocytes
- 12–15% reduction at 72 weeks (SURMOUNT-1 DEXA analysis)
- 2.5mg → 15mg weekly over 20 weeks
- Outperforms semaglutide in head-to-head trials. Highest total visceral fat loss
- Tesamorelin
- GHRH analog. Pulsatile GH release targeting visceral depots
- 15.2% reduction at 26 weeks (FDA lipodystrophy trial)
- 2mg subcutaneous daily before bed
- FDA-approved for HIV lipodystrophy. Proven visceral-specific effect
- CJC-1295 + Ipamorelin
- GH secretagogues. JAK2/STAT5 lipolysis pathway
- 6.8% reduction at 12 weeks (JCEM 2019)
- 200–300mcg each, 1–2x daily fasted
- Research-grade alternative to exogenous GH. Moderate visceral effect
- AOD9604
- GH fragment. Β3-adrenergic lipolysis, no IGF-1 elevation
- Limited human imaging data; 2.6kg total fat loss (Obesity Research trial)
- 300–500mcg daily subcutaneous, fasted
- Lacks direct visceral imaging evidence. Mechanism suggests preferential effect but unproven